Management, Biomarkers and Prognosis in People Developing Endocrinopathies Associated with Immune Checkpoint Inhibitors

Overview

Journal Nat Rev Endocrinol

Date 2025 Jan 8

PMID 39779950

Authors

Shintaro Iwama

Tomoko Kobayashi

Hiroshi Arima

Affiliations

Soon will be listed here.

Abstract

Immune-related adverse events (irAEs), including endocrine irAEs, can occur in response to cancer immunotherapy using immune checkpoint inhibitors (ICIs). Of the endocrine irAEs, pituitary and thyroid irAEs are most frequently observed, followed by primary adrenal insufficiency, type 1 diabetes mellitus and hypoparathyroidism. Notably, pituitary irAEs and type 1 diabetes mellitus can be lethal if overlooked, potentially leading to adrenal crisis and diabetic ketoacidosis, respectively. On the other hand, pituitary and thyroid irAEs are reported to be associated with more favourable prognoses in some cancers if treated appropriately with hormone-replacement therapies. It would be useful to identify those people who are likely to develop endocrine irAEs before initiating therapy with ICIs. Anti-pituitary antibodies and thyroid autoantibodies have been identified as potential biomarkers for the development of pituitary and thyroid irAEs, respectively. This Review elaborates on the clinical characteristics and management strategies of several endocrine irAEs, using the latest research findings and guidelines published by several academic societies.

References

Byun D, Wolchok J, Rosenberg L, Girotra M . Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017; 13(4):195-207. PMC: 5629093. DOI: 10.1038/nrendo.2016.205. View

Wright J, Powers A, Johnson D . Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021; 17(7):389-399. PMC: 8769055. DOI: 10.1038/s41574-021-00484-3. View

Maria Corsello S, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F . Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013; 98(4):1361-75. DOI: 10.1210/jc.2012-4075. View

Maker A, Yang J, Sherry R, Topalian S, Kammula U, Royal R . Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006; 29(4):455-63. PMC: 2134804. DOI: 10.1097/01.cji.0000208259.73167.58. View

Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello S . Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist. 2012; 17(4):525-35. PMC: 3336822. DOI: 10.1634/theoncologist.2011-0404. View

Jessel S, Weiss S, Austin M, Mahajan A, Etts K, Zhang L . Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. Front Oncol. 2022; 12:836859. PMC: 8958012. DOI: 10.3389/fonc.2022.836859. View

Vardarli I, Tan S, Brandenburg T, Weidemann F, Gorges R, Herrmann K . Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2023; 109(4):1132-1144. DOI: 10.1210/clinem/dgad670. View

Schneider B, Naidoo J, Santomasso B, Lacchetti C, Adkins S, Anadkat M . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021; 39(36):4073-4126. DOI: 10.1200/JCO.21.01440. View

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C . Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(12):1217-1238. DOI: 10.1016/j.annonc.2022.10.001. View

10.

Brahmer J, Abu-Sbeih H, Ascierto P, Brufsky J, Cappelli L, Cortazar F . Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021; 9(6). PMC: 8237720. DOI: 10.1136/jitc-2021-002435. View

11.

Arima H, Iwama S, Inaba H, Ariyasu H, Makita N, Otsuki M . Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr J. 2019; 66(7):581-586. DOI: 10.1507/endocrj.EJ19-0163. View

12.

Kobayashi T, Iwama S, Arima H . Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events. Endocr J. 2023; 71(1):23-29. DOI: 10.1507/endocrj.EJ23-0524. View

13.

Postow M, Sidlow R, Hellmann M . Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378(2):158-168. DOI: 10.1056/NEJMra1703481. View

14.

Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M . Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. 2020; 8(2). PMC: 7328763. DOI: 10.1136/jitc-2020-000779. View

15.

Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman H, Larman T . Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol. 2016; 186(12):3225-3235. PMC: 5225294. DOI: 10.1016/j.ajpath.2016.08.020. View

16.

Kanie K, Iguchi G, Bando H, Fujita Y, Odake Y, Yoshida K . Two Cases of Atezolizumab-Induced Hypophysitis. J Endocr Soc. 2018; 2(1):91-95. PMC: 5774896. DOI: 10.1210/js.2017-00414. View

17.

Faje A, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K . High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018; 124(18):3706-3714. DOI: 10.1002/cncr.31629. View

18.

Kurokawa R, Ota Y, Gonoi W, Hagiwara A, Kurokawa M, Mori H . MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis. AJNR Am J Neuroradiol. 2020; 41(9):1683-1689. PMC: 7583108. DOI: 10.3174/ajnr.A6692. View

19.

Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen J, Sullivan R . Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019; 181(3):211-219. DOI: 10.1530/EJE-19-0238. View

20.

Caturegli P, Newschaffer C, Olivi A, Pomper M, Burger P, Rose N . Autoimmune hypophysitis. Endocr Rev. 2005; 26(5):599-614. DOI: 10.1210/er.2004-0011. View